Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease
Abstract Plasma biomarkers that reflect specific amyloid beta (Abeta) proteoforms provide an insight in the treatment effects of Alzheimer’s disease (AD) therapies. Our aim was to develop and validate ready-to-use Simoa ‘Amyblood’ assays that measure full length Abeta1-42 and Abeta1-40 and compare t...
Guardado en:
Autores principales: | Elisabeth H. Thijssen, Inge M. W. Verberk, Jeroen Vanbrabant, Anne Koelewijn, Hans Heijst, Philip Scheltens, Wiesje van der Flier, Hugo Vanderstichele, Erik Stoops, Charlotte E. Teunissen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/783c572408a54a5796b786b326983e7c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Toll-->NFkappaB signaling pathway mediates the neuropathological effects of the human Alzheimer's Abeta42 polypeptide in Drosophila.
por: Lihua Tan, et al.
Publicado: (2008) -
Ginkgo biloba extract ameliorates oxidative phosphorylation performance and rescues abeta-induced failure.
por: Virginie Rhein, et al.
Publicado: (2010) -
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Sherif Bayoumy, et al.
Publicado: (2021) -
Immunochromatographic strip for ultrasensitive detection of fumonisin B1
por: Kai Hao, et al.
Publicado: (2018) -
Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression
por: Filip Liebsch, et al.
Publicado: (2019)